Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 9
Treatment-assignment count: 0
Stratification count: 0
NSCLC · Small Molecule Inhibitor
HER2 / ERBB2 expression is flagged as manual review required because public trials show inclusion required evidence in 17 contexts. FDA CDx context should be reviewed manually.
Strongest role: Inclusion Required
Inclusion-required count: 9
Treatment-assignment count: 0
Stratification count: 0
Threshold count: 10
Common snippets: BRAF V600E | MET exon 14 skipping | BRAF V600E
Threshold label: Moderate
CDx label: Fda Cdx Context Manual Review Required
CDx maturity score: 2/5
Confidence: Low
Signal count: 0
Recent signals: 0
Density label: Low
https://clinicaltrials.gov/study/NCT01121575 | https://clinicaltrials.gov/study/NCT01608022 | https://clinicaltrials.gov/study/NCT00079235 | https://clinicaltrials.gov/study/NCT06185400 | https://clinicaltrials.gov/study/NCT05751018 | https://clinicaltrials.gov/study/NCT05153408 | https://clinicaltrials.gov/study/NCT04382300 | https://clinicaltrials.gov/study/NCT07315113 | https://clinicaltrials.gov/study/NCT04201756 | https://clinicaltrials.gov/study/NCT03399487 | https://clinicaltrials.gov/study/NCT07012031 | https://clinicaltrials.gov/study/NCT05234606 | https://clinicaltrials.gov/study/NCT04285671 | https://clinicaltrials.gov/study/NCT03865511 | https://clinicaltrials.gov/study/NCT03228667 | https://clinicaltrials.gov/study/NCT03236935 | https://clinicaltrials.gov/study/NCT06031688